Congress demands full disclosure of secret drug pricing deals with manufacturers

What it does

This bill requires the Department of Health and Human Services to publicly release all documents, contracts, and communications related to drug pricing agreements struck between the federal government and pharmaceutical manufacturers since January 20, 2025—including deals involving most-favored-nation pricing, direct-to-consumer sales, import duty exemptions, and special regulatory treatment. The bill names 17 specific manufacturers with whom such agreements were announced, mandates disclosure within 30 days, and requires Congress and independent auditors to analyze the economic and budgetary effects of these deals on drug prices and federal programs.

Why we flagged it

The bill's core mechanism is compulsory public disclosure of previously confidential government-manufacturer agreements, paired with independent congressional and GAO analysis of their fiscal and competitive effects. It is a transparency and accountability tool, not a substantive pricing policy.

What the text implies

• Disclosure of 'proprietary pricing information' may be heavily redacted under permitted withholdings, potentially limiting the transparency benefit if manufacturers claim broad confidentiality protections under foreign law or settlement agreements.
• The bill does not mandate renegotiation or cancellation of existing agreements—it only requires disclosure. Citizens may learn what deals were struck but have no direct remedy if terms are unfavorable.
• CBO/GAO analysis is required to measure 'direct cost savings' by insurance status, which may reveal that uninsured individuals received minimal or no benefit from these agreements, exposing distributional inequity.
• The bill's reference to 'TrumpRx' and specific announcement dates (January 20, 2025 onward) signals this is a retrospective audit of a particular administration's drug deals, which may invite partisan challenge or future repeal.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens gain transparency into how federal drug pricing negotiations affect their out-of-pocket costs and insurance premiums, and Congress gains independent analysis of whether these deals deliver promised savings. The bill restricts government secrecy and manufacturer confidentiality claims—both forms of power asymmetry that typically harm public accountability—without blocking any citizen rights or remedies.

Named in the bill

Department of Health and Human Services, AbbVie Inc., Amgen Inc., AstraZeneca plc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Eli Lilly & Company, EMD Serono Inc., Genentech, Inc., Gilead Sciences, Inc., GSK plc., Johnson & Johnson, Inc. — and 8 more

Where it stands

24 cosponsors: 24 Democrats.

• Jul 15, 2026 — Introduced · Congress.gov: “Introduced in House”
• Jul 15, 2026 — Referred to House Committee on the Budget and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.